Data gathered: July 14
Alternative Data for NRx Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,839 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 39 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,938 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,507 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 14 | Sign up | Sign up | Sign up |
About NRx Pharmaceuticals
A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
| Price | $3.21 |
| Target Price | Sign up |
| Volume | 118,350 |
| Market Cap | $63M |
| Year Range | $1.16 - $5.1 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of “Buy” by BrokeragesJuly 10 - ETF Daily News |
 |
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry ClinicJuly 8 - Yahoo |
|
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100June 30 - Yahoo |
NRx Pharmaceuticals, Inc.(NasdaqCM: NRXP) added to Russell Microcap IndexJune 29 - Finnhub |
|
NRx Pharmaceuticals, Inc.(NasdaqCM: NRXP) added to Russell Microcap Growth IndexJune 29 - Finnhub |
|
NRx Pharmaceuticals, Inc.(NasdaqCM: NRXP) added to Russell 3000E Growth IndexJune 29 - Finnhub |
|
Insider Transactions View All
| Javitt Jonathan C filed to buy 84,634 shares at $1.2. December 18 '24 |
| Hurvitz Chaim filed to buy 570,000 shares at $0.3. September 11 '23 |
| Gorovitz Aaron filed to buy 105,000 shares at $0.3. September 11 '23 |
| Javitt Jonathan C filed to buy 446,332 shares at $0.3. August 24 '23 |
| Javitt Jonathan C filed to buy 346,332 shares at $0.3. August 23 '23 |
Similar companies
Read more about NRx Pharmaceuticals (NRXP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of NRx Pharmaceuticals?
The Market Cap of NRx Pharmaceuticals is $63M.
What is the current stock price of NRx Pharmaceuticals?
Currently, the price of one share of NRx Pharmaceuticals stock is $3.21.
How can I analyze the NRXP stock price chart for investment decisions?
The NRXP stock price chart above provides a comprehensive visual representation of NRx Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NRx Pharmaceuticals shares. Our platform offers an up-to-date NRXP stock price chart, along with technical data analysis and alternative data insights.
Does NRXP offer dividends to its shareholders?
As of our latest update, NRx Pharmaceuticals (NRXP) does not offer dividends to its shareholders. Investors interested in NRx Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NRx Pharmaceuticals?
Some of the similar stocks of NRx Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.